Delandistrogene moxeparvovec
PreclinicalGene therapy
Sarepta TherapeuticsDelandistrogene moxeparvovec is a gene therapy that works as a Micro-Dystrophin Gene Therapy.[1] It is being investigated across 1 indication, with its most advanced program in Preclinical.
Delandistrogene moxeparvovec is one of 42 gene therapy programs targeting Duchenne Muscular Dystrophy. It is currently in Preclinical.
1
Indications
0
Total Trials
0
Active Trials
41
Competitors
Pipeline
Status by Indication[2]
Indication
Competition
Competitive Landscape
125 competitors in Duchenne Muscular Dystrophy
#DrugCompanyPhaseTrials
1Cialis
Eli LillyPhase 3
Aldactone
PfizerPhase 3
Rifadin
SanofiPhase 3
Nolvadex
AstraZenecaPhase 3
Avicel
SSanthera Pharmaceuticals
Phase 3
Rayos
RRoxane Laboratories
Phase 3
Inspra
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Duvyzat
ItalfarmacoPhase 3
Bystolic
VVitae Pharmaceuticals Inc., an Allergan affiliate
Phase 3
ENSPRYNG
RochePhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Micro-Dystrophin Gene Therapy[1]
- Modality
- Gene therapy[1]
- Highest Phase
- Preclinical
- Company